Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03872206 · ClinicalTrials.gov registry record · Phase 1
Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression
A Phase 1 study, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
NCT03872206: Completed Phase 1 study, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
NCT03872206 is a Phase 1 study that has completed, run by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 95 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03872206, a Phase 1 study, has completed, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
An open-label, Phase 1/2a study of HPN536 as monotherapy to assess the safety, tolerability and PK in patients with advanced cancers associated with mesothelin expression.(Phase 2 portion of the study was not conducted.)
Primary Outcome
Assess safety and tolerability at increasing dose levels of HPN536 in successive cohorts of patients with of patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, pancreatic adenocarcinoma, or mesothelioma (pleural and primary peritoneal) by adverse events (CTCAE v5.0)
Interventions
- BIOLOGICAL HPN536 Fixed IV 6 to 560 ng/kg
- BIOLOGICAL HPN536 1 Prime Step IV 600-1200 ng/kg Target
- BIOLOGICAL 2 Prime Step IV 900-14000 ng/kg Target
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2019-04-16 |
| Est. Completion | 2023-01-04 |
| Phase | Phase 1 |
Sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4 total trials
What the finished NCT03872206 record still lists
NCT03872206 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% higher).
The record links to 0 conditions, and to 3 interventions - of which HPN536 Fixed IV 6 to 560 ng/kg is the first listed.
NCT03872206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03872206 about?
NCT03872206 is a clinical study titled "Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression". An open-label, Phase 1/2a study of HPN536 as monotherapy to assess the safety, tolerability and PK in patients with advanced cancers associated with mesothelin expression.(Phase 2 portion of the study was not conducted.)
What is the current status of trial NCT03872206?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2019-04-16. Estimated completion is 2023-01-04.
What interventions are being tested in trial NCT03872206?
The interventions under investigation include: HPN536 Fixed IV 6 to 560 ng/kg (BIOLOGICAL), HPN536 1 Prime Step IV 600-1200 ng/kg Target (BIOLOGICAL), 2 Prime Step IV 900-14000 ng/kg Target (BIOLOGICAL).
Who is sponsoring clinical trial NCT03872206?
This trial is sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03872206's enrollment target sits among peer trials
95 610th of 2000 higher than 1,386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI